Provention Bio Inc

NASDAQ:PRVB  
6.10
-0.06 (-0.97%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)383.46M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.18 Million
Adjusted EPS-$0.52
See more estimates
10-Day MA$6.43
50-Day MA$7.66
200-Day MA$11.89
See more pivots

Provention Bio Inc Stock, NASDAQ:PRVB

55 Broad Street, 2nd floor, Red Bank, New Jersey 07701
United States of America
Phone: +1.908.428.9136
Number of Employees:

Description

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohnâ??s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.